LHP842

LHP842 is an investigational drug candidate being developed by Lighthouse Pharmaceuticals. While specific details regarding its molecular target and clinical phase are limited, it is part of the company's pipeline of gingipain inhibitors. These are small molecule protease inhibitors designed to target the virulence factors (gingipains) of the bacterium *Porphyromonas gingivalis*, which is implicated in the pathogenesis of Alzheimer's disease and other chronic inflammatory conditions. LHP842 is a next-generation candidate following the company's lead programs, LHP588 and atuzaginstat, and is currently in early-stage development, categorized as either preclinical or Phase 1.